2021 was a banner year for the women’s health and wellness industry as global venture capital investment in FemTech companies surpassed $1B for the first time. This was attributable to a number of high value deals in the sector, including Elvie’s $97M Series C fundraise and Maven’s $110M Series D fundraise, which resulted in Maven becoming the first FemTech unicorn. In this article, Goodwin Life Sciences partner Sophie McGrath and associate Kesten Laverty explore areas ripe for future growth within the women’s health and wellness industry. Read the Maddyness UK article here.
In The Press 17 May 2022